Is kidney injury from Gemcitabine reversible?

Variable. Typical onset: Delayed — months of cumulative exposure..

How should kidney function be monitored during Gemcitabine therapy?

Check CBC with peripheral smear (schistocytes), LDH, haptoglobin, and creatinine before each cycle — look for the MAHA triad of falling platelets/hemoglobin, rising LDH, and rising creatinine.; Monitor blood pressure at every visit and have patients self-monitor; new or accelerating/malignant hypertension often precedes the renal/hematologic diagnosis of gemcitabine-TMA by days to weeks.; Track cumulative gemcitabine dose and treatment duration — risk rises with prolonged exposure (median onset ~8 months, cumulative doses ~9-56 g/m2 in reported series).; Screen urine for new or worsening proteinuria and hematuria, which reflect the evolving glomerular/vascular injury.; If TMA labs appear, send ADAMTS13 activity to exclude TTP (gemcitabine-TMA has near-normal ADAMTS13) and stop the drug immediately rather than waiting for biopsy confirmation..

How can kidney injury from Gemcitabine be prevented?

No proven pharmacologic prophylaxis

Who is at higher risk of kidney injury from Gemcitabine?

High cumulative dose; Prior mitomycin; Hypertension.

Back to explorer

Printable monograph

Nucleoside analog

Gemcitabine

Gemzar · Gem

Nucleoside analog · approved 1996 · 14 citations · FAERS AKI reporting ROR 2.77 (95% CI 2.61–2.95, 1,049 AKI reports)

Up to date· through 2026

Deeply sourced9/9 · 8 signals

Met: 14 citations
Met: 12+ references
Met: Accrued over 10+ years (span: 27y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2026
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

The silent TMA — new hypertension months in is the warning sign.

SevereNucleoside analog

PancreaticBladderLungBreastOvarian

§01

Signature kidney injury

Signature lesion

Thrombotic Microangiopathy

Representative incidence0.015%

0.008–0.078% range across studies

Estimates span three orders of magnitude by ascertainment. The only figure with a real denominator is the manufacturer safety-database review: 12 cases against 78,800 patient exposures, a crude 0.015% (range 0.008–0.078%). The product characteristics give 0.01%. Against that, a single center reported 2.7% — four of its five cases on nab-paclitaxel/gemcitabine, where a pharmacokinetic interaction is suspected. Historically high mortality: of 23 cases with reported outcome in the literature tally, 11 died within a few weeks, death directly attributed to HUS in two.Source: Fung et al., Cancer 1999 (PMID 10223245); Allard et al., Eur J Clin Pharmacol 2022 (PMID 35507073); Walter et al., Am J Kidney Dis 2002 (PMID 12324937)

Onset & rechallenge

Time to injuryDelayed (>6 weeks / cumulative)

TMA emerges after months of cumulative exposure, not from a single dose.

Distilled from: “Delayed — months of cumulative exposure.”

RechallengeContraindicated on rechallenge

Once TMA is suspected the drug is stopped permanently; rechallenge risks recurrence and worse renal outcomes.

Long-term outlook & thresholds

Renal recoveryVariable

Renal recovery is genuinely split. Renal-limited TMA can reverse after prompt, permanent drug cessation, but a meaningful subset progresses to dialysis-dependent kidney failure or chronic CKD despite discontinuation. Discontinuation is the key intervention — dose reduction neither prevents nor reverses it, and plasma exchange is generally ineffective (this is not classic TTP).PMID 12324937 (opens PubMed in a new tab)

CKD trajectory.: A subset is left with chronic renal insufficiency / CKD after the acute TMA.
Dialysis / RRT.: A meaningful subset develops kidney failure requiring dialysis, sometimes dialysis-dependent.
Outcome marker.: Historically high mortality: in the pooled Walter review 11 of 23 patients with reported outcome died within weeks (death directly attributable to HUS in 2).

Cumulative-dose threshold

Median cumulative dose ~20 g/m2 (range ~2.5-48 g/m2), reached over roughly 22 doses and a mean of ~7.4 months of therapy (median onset ~8 months).

A cumulative-dose/duration phenomenon rather than an idiosyncratic single-dose reaction: risk rises with prolonged exposure, so vigilance must persist throughout treatment. Dose reduction does not prevent it — once TMA is suspected the drug must be permanently discontinued.PMID 12324937 (opens PubMed in a new tab)

Early-detection biomarkers

New or worsening (accelerated/malignant) hypertension — Early glomerular endothelial / microvascular injury preceding overt TMA. The earliest clinical marker of gemcitabine-associated TMA: new or exacerbated hypertension was prominent in 7 of 9 patients and preceded clinical diagnosis by 0.5-10 weeks, proposed as a useful early identifier. New hypertension on gemcitabine should trigger urgent MAHA labs rather than simply adding an antihypertensive.PMID 15197810 (opens PubMed in a new tab)
Microangiopathic hemolysis panel (schistocytes on smear, rising LDH, falling haptoglobin, thrombocytopenia) — Mechanical intravascular red-cell fragmentation from microvascular thrombi (MAHA). The diagnostic MAHA triad — falling platelets and hemoglobin, rising LDH, schistocytes — alongside rising creatinine defines the syndrome; ADAMTS13 activity is near-normal, distinguishing gemcitabine-TMA from TTP.PMID 12324937 (opens PubMed in a new tab)
Complement activation (terminal pathway / soluble C5b-9) — Complement pathway over-activation driving the endothelial microangiopathy. Gemcitabine-associated HUS/TMA involves over-activation of the complement pathway, providing the rationale for terminal-complement blockade (eculizumab) in refractory or severe disease.PMID 33717763 (opens PubMed in a new tab)

Long-term outcome and threshold data distilled from the agent's cited literature — educational, not a substitute for the primary sources.

Recovery across agents

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Thrombotic Microangiopathy#1 · Signature0.31%PMID 15197810 (opens PubMed in a new tab)
Cumulative incidence 0.31% in the largest single-institution series (8/2586 patients); older estimates ~0.015% and pooled ranges 0.015-1.4%. Dose-dependent, risk rises as cumulative dose approaches ~20,000 mg/m2.
HypertensionSecondaryno population incidence denominator
New or exacerbated hypertension is a prominent early feature of gemcitabine-associated TMA, seen in 7 of 9 patients and often preceding TMA diagnosis by 0.5-10 weeks. PMID 15197810 (opens PubMed in a new tab)
Glomerular Injury / ProteinuriaRareno population incidence denominator
Glomerular endothelial injury underlies the TMA lesion; gemcitabine is listed among conventional chemotherapies causing glomerular disease, but standalone incidence is case-level with no citable rate. PMID 35190107 (opens PubMed in a new tab)
Hemorrhagic CystitisRarequalitative — no citable incidence
Intravesical instillation only - chemical/follicular cystitis in NMIBC trials, not a systemic-route toxicity.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

0.0%incidence

SeveritySevere

ReversibilityVariable

Evidence14 citations

Nephron map

GlomerulusFiltration barrier (podocytes + endothelium)

Vasculature / EndotheliumGlomerular & peritubular capillaries

Bladder / Urothelium

Thrombotic Microangiopathy

Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

§03

Kidney injury

Deep diveGemcitabine and mitomycin thrombotic microangiopathyTwo old cytotoxics — mitomycin and gemcitabine — injure the microvascular endothelium directly and in proportion to the cumulative dose, so months into therapy the small vessels clot, red cells shear, platelets fall, and the kidney fails: a dose-dependent thrombotic microangiopathy that is not TTP, does not respond to plasma exchange, and is answered first by stopping the drug.Appears in 2 documented synergy combinations

Mechanism of kidney injury

Direct, dose-cumulative glomerular endothelial toxicity creates microvascular thrombi, mechanically fragmenting red cells and consuming platelets. Onset a mean 7.4 ± 3.5 months and 21.9 ± 10.9 doses in, at a median cumulative dose of 20 g/m² (range 2.45–48 g/m²).

Clinical presentation

New or worsening hypertension (often the earliest sign), microangiopathic hemolytic anemia with schistocytes, thrombocytopenia, AKI and proteinuria.

Management

Discontinue gemcitabine (the key step), control BP, supportive care; eculizumab in refractory/severe cases. Plasma exchange is generally ineffective.Lesion-level management framework

Risk factors

High cumulative dose
Prior mitomycin
Hypertension

Prevention

No proven pharmacologic prophylaxis

Anticancer mechanism· how it treats cancer

Nucleoside analog incorporated into DNA, causing chain termination and inhibiting ribonucleotide reductase. Pancreatic, bladder, lung, breast and ovarian cancer.

Note · New hypertension during gemcitabine should trigger a TMA workup.

§04

Clinical depth

Renal dose adjustment

No formal renal dose adjustment is specified in the FDA label, which advises caution in renal impairment given limited data; many centers use gemcitabine cautiously at standard or modestly reduced doses with close monitoring rather than a fixed CrCl-based reduction. Critically, dose reduction does not prevent gemcitabine-associated TMA, which is a cumulative-dose/duration phenomenon — once TMA is suspected, the drug must be permanently discontinued rather than dose-reduced.

Dialyzability & ESKD dosing

Gemcitabine and its active metabolite dFdU are renally cleared, and dFdU accumulates markedly in severe renal impairment; the parent drug has a short half-life and is partly cleared by intermittent hemodialysis, but pharmacokinetic data in HD are limited. When gemcitabine is given to dialysis patients (rare, individualized), some protocols administer it 6-12 hours before HD to limit dFdU accumulation; supportive data are sparse and this remains expert-opinion rather than label-driven.

Differential diagnosis

Gemcitabine-TMA must be distinguished from TTP (gemcitabine-TMA shows normal or only mildly reduced ADAMTS13 and does not respond reliably to plasma exchange) and from Shiga toxin/complement-mediated HUS (no diarrheal prodrome; usually no pathogenic complement mutation). The combination of subacute onset after months of therapy, prominent new/malignant hypertension, and a compatible cumulative dose points to gemcitabine rather than disease progression, contrast nephropathy, or other drug causes such as mitomycin-C or VEGF inhibitors.

Monitoring

Check CBC with peripheral smear (schistocytes), LDH, haptoglobin, and creatinine before each cycle — look for the MAHA triad of falling platelets/hemoglobin, rising LDH, and rising creatinine.
Monitor blood pressure at every visit and have patients self-monitor; new or accelerating/malignant hypertension often precedes the renal/hematologic diagnosis of gemcitabine-TMA by days to weeks.
Track cumulative gemcitabine dose and treatment duration — risk rises with prolonged exposure (median onset ~8 months, cumulative doses ~9-56 g/m2 in reported series).
Screen urine for new or worsening proteinuria and hematuria, which reflect the evolving glomerular/vascular injury.
If TMA labs appear, send ADAMTS13 activity to exclude TTP (gemcitabine-TMA has near-normal ADAMTS13) and stop the drug immediately rather than waiting for biopsy confirmation.

Key trials & series

Humphreys et al. 2004 (Cancer) — largest single-institution series of gemcitabine-associated TMA (incidence ~0.31%, higher than prior 0.015% estimates); new or exacerbated hypertension in 7/9 patients preceded diagnosis and was proposed as an early warning sign.
Glezerman et al. 2009 (Ann Pharmacother, MSKCC) — cohort analysis linking gemcitabine-associated HUS/TMA to cumulative dose and treatment duration, supporting a dose-dependent toxic mechanism.
Saif & McGee 2005 (JOP) — case report plus literature review establishing gemcitabine-induced HUS as a distinct, often irreversible entity (biopsy-proven TMA progressing to dialysis despite plasmapheresis and steroids).
Ritchie et al. 2016 (Cancer Chemother Pharmacol) — retrospective rituximab case series in gemcitabine-HUS reporting durable hematologic and renal recovery when plasma exchange failed, informing complement/immune-directed rescue therapy.

Clinical pearls

Hypertension is the clinical tell: new-onset or accelerated/malignant hypertension frequently heralds gemcitabine-TMA and should trigger urgent MAHA labs rather than simply adding an antihypertensive.
Gemcitabine-TMA is dose/duration-cumulative, not idiosyncratic to a single dose — it typically emerges after many months of therapy, so vigilance must persist throughout treatment, not just at initiation.
The cornerstone of management is permanent drug discontinuation; dose reduction or rechallenge risks recurrence and worse renal outcomes.
Plasma exchange is often ineffective (this is not classic TTP); renal recovery is variable and a meaningful subset progress to dialysis-dependent kidney failure or chronic CKD.
Complement activation is implicated (gemcitabine renal biopsies show prominent capillary complement deposition), providing the rationale for anti-complement therapy (e.g., eculizumab) or rituximab as rescue when TMA persists after drug withdrawal.
Chemical/follicular cystitis is an intravesical-route gemcitabine toxicity (NMIBC instillation trials); systemic-gemcitabine hemorrhagic cystitis is undocumented, and the urothelial-cancer indication inflates the FAERS term.

Beyond the kidney — non-renal toxicities· 4 organ systems

Class-level context for the major non-renal toxicities of the Nucleoside analog class.

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

Mucositis and diarrhea

Hepatic / Liver

Transaminitis, hepatitis, VOD/SOS

Transaminitis (methotrexate)

Hematologic

Cytopenias, thrombosis, TMA

Myelosuppression

Pulmonary

Pneumonitis, ILD, effusions, hypertension

Methotrexate / gemcitabine pneumonitis

§05

References

10 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

10 references · 1999–2026 · 1 since 2024

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 4

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateEculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report.Chewcharat A et al. · Am J Kidney Dis 2025 · PMID 4082547072-year-old with metastatic pancreatic adenocarcinoma; biopsy-confirmed gemcitabine/nab-paclitaxel TMA (MAHA, thrombocytopenia, AKI). Strong causality with dechallenge improvement and protected rechallenge under prophylactic eculizumab without recurrence. High-quality AJKD case.CaseB · ModerateGemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.Katagiri D et al. · CEN Case Rep 2018 · PMID 29766468Biopsy-proven gemcitabine-induced thrombotic microangiopathy presenting with acute kidney injury and nephrotic syndrome in a pancreatic cancer patient.CaseC · LimitedGemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report.Van den Eeckhaut L et al. · J Gastrointest Oncol 2022 · PMID 3663605446-year-old with pancreatic adenocarcinoma developed dialysis-dependent gemcitabine-induced TMA refractory to plasmapheresis/steroids; renal recovery (off dialysis, Cr 1 mg/dL) after eculizumab. Illustrates complement-targeted therapy in gemcitabine TMA.CaseC · LimitedGemcitabine-Induced Thrombotic Microangiopathy in a Patient With Cholangiocarcinoma: An Atypical Case.Anil V et al. · Cureus 2024 · PMID 39070506Atypical gemcitabine-induced thrombotic microangiopathy presenting as AKI and hypertension lacking classic hematologic features, progressing to end-stage renal disease requiring hemodialysis.

Conference abstracts & journal reports· 2 non-PubMed

Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.

AbstractLight at the End of the Tunnel: A Case of Eculizumab in Gemcitabine-Induced Thrombotic MicroangiopathyASN Kidney Week 2024 2024 · Abstract PUB052Classic gemcitabine TMA triad (microangiopathic hemolysis, thrombocytopenia, AKI) that continued to worsen after drug cessation; biopsy-confirmed and treated with weekly eculizumab with partial renal recovery — adding to the case for complement blockade in refractory drug-induced TMA.AbstractLong-Term Kidney Outcomes in Gemcitabine-Bevacizumab-Induced Thrombotic Microangiopathy Treated with Complement Inhibition: A Case SeriesShukla P, Bertan SH, Kelly A, Gudsoorkar PS, Gupta S, Hanna P · ASN Kidney Week 2025 2025 · Abstract SA-PO0206A four-patient series of gemcitabine/bevacizumab drug-induced TMA (mean creatinine 2.88 mg/dL) treated with C5 (complement) inhibition reporting improved long-term kidney outcomes — adding longitudinal follow-up to the case for complement blockade in refractory chemotherapy-associated TMA.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 53,013 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 8 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Thrombotic Microangiopathycorroborated · ROR 35.79
Glomerular Injury / Proteinuriacorroborated · ROR 3.79 — on the terms that name the lesion (ROR 2.62)
Hemorrhagic Cystitiscorroborated · ROR 1.82 — on the terms that name the lesion (ROR 3.77)
HypertensionNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.

Thrombotic Microangiopathy

ROR 35.7995% CI 33.76–37.94· 1,259 reports

Glomerular Injury / Proteinuria

ROR 3.7995% CI 3.37–4.27· 276 reports

SIADH / Hyponatremia

ROR 2.9795% CI 2.74–3.22· 598 reports

Electrolyte Disturbance

ROR 2.9695% CI 2.81–3.12· 1,398 reports

Acute Tubular Necrosis

ROR 2.4295% CI 1.88–3.13· 60 reports

Acute Interstitial Nephritis

ROR 2.1095% CI 1.72–2.56· 99 reports

Hemorrhagic Cystitis

ROR 1.8295% CI 1.63–2.04· 318 reports

Crystal / Obstructive Nephropathy

ROR 1.1995% CI 1.03–1.39· 168 reports

FAERS outcomes & reporting trend· 18.8% of reports w/ death · 39.7% w/ hospitalization

18.8%

Reported with a death outcome

9,972 of 53,013 reports

39.7%

Reported with hospitalization

21,057 of 53,013 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 7 systems · 53,013 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 2.7795% CI 2.61–2.95· 1,049 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Blood & lymphatic

Thrombocytopenia3,705Neutropenia3,294Anaemia3,084Febrile Neutropenia1,835Myelosuppression1,657

Gastrointestinal

Nausea2,607Diarrhoea2,120Vomiting2,099Abdominal Pain1,223

General / constitutional

Pyrexia2,595Fatigue2,096Asthenia1,531

Immune / infection

Pneumonia1,471Sepsis1,256

Respiratory

Dyspnoea1,612

Nervous system

Neuropathy Peripheral1,302

Metabolic & electrolyte

Decreased Appetite1,119

Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ADQIConventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) WorkgroupKidney Int 2026 · PMID 41881107Cisplatin is identified as a leading cytotoxic nephrotoxin; the workgroup details preventive measures (adequate isotonic hydration, correction of volume depletion, avoidance of concurrent nephrotoxins, attention to electrolyte/magnesium wasting) and management of cisplatin-associated AKI, with a research agenda for knowledge gaps.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Gemcitabine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Mitomycin C

Mutamycin · Antitumor antibiotic

Profile

Prototype dose-dependent TMA.

TMAGLOMCYST

Severe#1 · 77% phenotype match

Ziv-aflibercept

Zaltrap · VEGF trap

Profile

Hypertension and proteinuria like bevacizumab.

HTNGLOMTMA

Moderate#2 · 72% phenotype match

Bevacizumab

Avastin · Anti-VEGF antibody

Profile

Proteinuria, hypertension, glomerular TMA.

GLOMHTNTMA

Moderate#3 · 72% phenotype match

Ramucirumab

Cyramza · Anti-VEGFR2 antibody

Profile

Hypertension and proteinuria, class effect.

HTNGLOMTMA

Moderate#4 · 72% phenotype match

VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)

VEGFR TKI

Profile

Hypertension as an on-target marker; proteinuria.

HTNGLOMTMA

Moderate#5 · 72% phenotype match

Pazopanib

Votrient · VEGFR TKI

Profile

VEGFR-TKI; hypertension, proteinuria, TMA.

GLOMHTNTMA

Moderate#6 · 70% phenotype match

Compare Gemcitabine with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Antimetabolites

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Gemcitabine’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Gemcitabine; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 218 clinical records among the 300 most-relevant of 325 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.